NeoGenomics Announces Pricing of $9.5 Million Public Offering

        NeoGenomics Announces Pricing of $9.5 Million Public Offering

3.15 Million Share Offering at $3.00 per Share

PR Newswire

FT. MYERS, Fla., Feb. 28, 2013

FT. MYERS, Fla., Feb. 28, 2013 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ:
NEO), a leading provider of cancer-focused genetic testing services, today
announced that it has priced an underwritten public offering of 3.15 million
shares of common stock at a price to the public of $3.00 per share. Of the
shares offered, NeoGenomics is selling 2.85 million shares and a selling
stockholder, The Mary S. Dent Gifting Trust, is selling 300,000 shares. The
transaction is expected to close on March 5, 2013 and will result in gross
proceeds to NeoGenomics of $8.6 million. The net proceeds to the Company,
after deducting the underwriter's discounts and other estimated offering
expenses, will be approximately $7.8 million. NeoGenomics will not receive
any proceeds from the sale of shares by the selling stockholder. The Company
plans to use the net proceeds to pay down certain indebtedness and for general
corporate and operating purposes. NeoGenomics has granted the underwriters a
30-day option to purchase up to an additional 472,500 shares of common stock
to cover over-allotments, if any.

Craig-Hallum Capital Group LLC is the book-running manager for the offering
with Ladenburg Thalmann & Co. Inc. and Emerging Growth Equities, Ltd. serving
as co-managers on the offering.

This offering is being conducted pursuant to a shelf registration statement
that was declared effective by the U.S. Securities and Exchange Commission
("SEC") on February 12, 2013. The offering is being made only by means of a
prospectus supplement and accompanying prospectus, forming an effective part
of the registration statement. A preliminary prospectus supplement and the
accompanying prospectus relating to these securities have been filed with the
SEC and are available at the SEC's website at www.sec.gov. Before investing,
you should read the prospectus supplement and the accompanying prospectus for
information about NeoGenomics, the selling stockholder and this offering.
Copies of the preliminary prospectus supplement, the final prospectus
supplement (when available) and accompanying prospectus relating to these
securities may also be obtained from Craig-Hallum Capital Group LLC at 222
South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, by calling
612-334-6300, or by emailing bart.federak@craig-hallum.com.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of such
jurisdiction.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that
specializes in cancer genetics testing, the fastest growing segment of the
laboratory industry. The company's testing services include cytogenetics,
fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, anatomic pathology and molecular genetic testing.
Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,
Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of
pathologists, oncologists, other clinicians and hospitals throughout the
United States. For additional information about NeoGenomics, visit
http://www.neogenomics.com.

Interested parties can also access investor relations material from Hawk
Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from
Zacks Investment Research at http://www.zacks.com or scr@zacks.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements. Actual results could differ materially from
such statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company's ability to continue gaining
new customers, offer new types of tests, and otherwise implement its business
plan. As a result, this press release should be read in conjunction with the
company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Website: http://www.neogenomics.com
Contact: NeoGenomics, Inc., Steven C. Jones, Director of Investor Relations,
+1-239-325-2001, sjones@neogenomics.com; Hawk Associates, Inc., Ms. Julie
Marshall, +1-305-451-1888, neogenomics@hawkassociates.com
 
Press spacebar to pause and continue. Press esc to stop.